MonoGerm clinical trial – is one chemotherapy medicine safer for germinomas?
Testing whether treatment could be safely reduced for children with germinoma brain tumours
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Testing whether treatment could be safely reduced for children with germinoma brain tumours
Finding the biological differences between teenage and young adult cancers cells compared to older adults.
Using Burkitt lymphoma models to find essential survival genes to target for therapy.
Investigating how cancer cells can keep dividing and why this makes it harder to treat.
Investigating how a protein changes the way leukaemia cells behave in babies.
Repurposing medicines to support a new type of immunotherapy for brain tumours.
Using anti-depressants to prevent the body's immune system from fighting immunotherapy treatments.
Understanding how leukaemia cells enlist immune system cells to help them survive chemotherapy.
Looking at how a process called 'cut-and-run' leads to genetic errors, and how those errors could be prevented in order to prevent relapse in childhood leukaemia.